Geode Capital Management LLC Has $1.43 Million Stock Holdings in Biodesix, Inc. (NASDAQ:BDSX)

Geode Capital Management LLC increased its position in shares of Biodesix, Inc. (NASDAQ:BDSX) by 50.7% during the third quarter, Holdings Channel reports. The institutional investor owned 804,576 shares of the company’s stock after purchasing an additional 270,724 shares during the period. Geode Capital Management LLC’s holdings in Biodesix were worth $1,433,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Barclays PLC increased its holdings in shares of Biodesix by 1,140.5% during the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after acquiring an additional 21,179 shares in the last quarter. CVI Holdings LLC acquired a new stake in Biodesix in the 2nd quarter valued at $59,000. Landscape Capital Management L.L.C. bought a new stake in Biodesix during the 3rd quarter valued at $262,000. Perkins Capital Management Inc. raised its holdings in Biodesix by 74.7% during the third quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after buying an additional 310,000 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new position in shares of Biodesix in the second quarter valued at $2,874,000. Institutional investors own 20.96% of the company’s stock.

Insiders Place Their Bets

In related news, Director Matthew Strobeck purchased 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were bought at an average cost of $1.40 per share, with a total value of $56,000.00. Following the acquisition, the director now owns 2,606,879 shares of the company’s stock, valued at $3,649,630.60. This represents a 1.56 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jack W. Schuler acquired 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were bought at an average price of $1.17 per share, with a total value of $234,000.00. Following the acquisition, the director now directly owns 31,094,935 shares of the company’s stock, valued at $36,381,073.95. The trade was a 0.65 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 315,000 shares of company stock valued at $393,500. Corporate insiders own 69.20% of the company’s stock.

Biodesix Trading Down 0.7 %

NASDAQ BDSX opened at $1.48 on Friday. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30. The business has a fifty day simple moving average of $1.39 and a 200 day simple moving average of $1.59. Biodesix, Inc. has a 12 month low of $1.11 and a 12 month high of $2.21. The firm has a market capitalization of $215.29 million, a P/E ratio of -3.79 and a beta of 1.10.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Friday, November 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The firm had revenue of $18.15 million during the quarter, compared to analyst estimates of $18.45 million. During the same quarter in the prior year, the business posted ($0.12) EPS. On average, analysts predict that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Scotiabank started coverage on shares of Biodesix in a research report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 target price for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $3.06.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.